NOTE: If you attended the live CE activity AND received CE credit (i.e. a pharmacist CE statement of credit with ACPE UAN 0221-9999-19-158-L01-P), you are NOT allowed to also receive credit for this home-study on-demand web activity.
|Co-produced by ProCE and the Society of Infectious Diseases Pharmacists Education Center (SIDPEC)|
This is a featured CE activity on the Society of Infectious Diseases Pharmacists Education Center (SIDPEC) website. SIDPEC is the educational hub of the Society of Infectious Diseases Pharmacists (SIDP). The SIDPEC portal provides educational activities on infectious disease pharmacotherapy for clinical pharmacists, health‐systems pharmacists, community pharmacists, and other allied‐health disciplines.
Vancomycin serves as a pivotal drug in the treatment of infectious diseases. In this activity, participants will better understand appropriate utilization of AUC-based dosing, including evidence-based support of usage and implementation strategies. A discussion for and against estimation of AUC values will be had, along with potential guideline changes practitioners may prepare for.
The target audience for this activity includes health‐system and infectious diseases pharmacists, including chief pharmacy officers and pharmacy directors. At the completion of this activity, the participant will be better able to:
- Discuss the data supporting an AUC-based dosing strategy for vancomycin.
- Describe anticipated recommendations from the upcoming vancomycin guidelines.
- Describe the different approaches and pros and cons for estimating vancomycin AUC exposures.
- Outline key strategies to successful implementation of an AUC based dosing protocol.
Michael J. Rybak, Pharm.D., M.P.H., Ph.D.
Professor of Pharmacy & Medicine
Anti-Infective Research Laboratory
Department of Pharmacy Practice
Eugene Applebaum College of Pharmacy & Health Sciences
Wayne State University
Jason M. Pogue, PharmD, BCPS, BCIDP
Clinical Professor, Infectious Diseases
Department of Clinical Pharmacy
University of Michigan College of Pharmacy
Release Date: 5-29-2019
Expiration Date: 5-29-2022
This activity is jointly provided by ProCE, Inc. and the Society of Infectious Diseases Pharmacists. ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-19-158-H01-P has been assigned to this home study knowledge-based activity. This activity is approved for 1.25 contact hour (0.125 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation to receive pharmacy CE credit. Statements of completion will be issued online at www.ProCE.com and proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.
It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation. Dr. Rybak has received Research Support from Allergan, and is a Speaker and/or Consultant for Achaogen, Bayer, Melinta, Merck, Nabriva, Shionogi, and Tetraphase. Dr. Pogue has received grant support from Merck, and is a Speaker and/or Consultant for Achaogen, Allergan, Melinta, Merck, Nabriva, Paratek, Shionogi, Tetraphase, and Zavante. A portion of grant funds received by ProCE from InsightRx will be used to compensate the faculty for this presentation.
This activity is supported by an educational grant from InsightRX.
The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.